Robert Bostwick
Southern Research Institute
25 Papers
66 Citations
Robert Bostwick is an academic researcher from Southern Research Institute. The author has contributed to research in topics: Biology & Chemistry. The author has an hindex of 10, co-authored 21 publications.
Chat about Author
Papers
Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2
Catherine Z. Chen,Paul Shinn,Zina Itkin,Richard T. Eastman,Robert Bostwick,Lynn Rasmussen,Ruili Huang,Min Shen,Xin Hu,Kelli M. Wilson,Brianna M. Brooks,Hui Guo,Tongan Zhao,Carleen Klump-Thomas,Anton Simeonov,Samuel G. Michael,Donald C. Lo,Matthew D. Hall,Wei Zheng +18 more
TL;DR: In this article, the authors carried out a quantitative high-throughput screen using a SARS-CoV-2 cytopathic assay with a compound collection of 8,810 approved and investigational drugs, mechanism-based bioactive compounds, and natural products.
A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion.
Jyoti Sharma,Ming Du,Eric Wong,Venkateshwar Mutyam,Yao Li,Jianguo Chen,Jamie R Wangen,Kari Thrasher,Lianwu Fu,Ning Peng,Liping Tang,Kaimao Liu,Bini Mathew,Robert Bostwick,Corinne E. Augelli-Szafran,Hermann Bihler,Feng Liang,Jerome Mahiou,Josef Saltz,Andras Rab,Jeong S. Hong,Eric J. Sorscher,Eric M. Mendenhall,Candice J. Coppola,Kim M. Keeling,Rachel Green,Martin Mense,Mark J. Suto,Steven M. Rowe,David M. Bedwell +29 more
TL;DR: In this article, the authors used an NMD-sensitive nanoLuc readthrough reporter to screen 771,345 compounds and identified 180 compounds with readthrough activity, including SRI-37240 and its more potent derivative SRI41315, induce a prolonged pause at stop codons and suppress PTCs associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells.
The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules.
Kirill Gorshkov,Catherine Z. Chen,Robert Bostwick,Lynn Rasmussen,Bruce Nguyen Tran,Yu-Shan Cheng,Miao Xu,Manisha Pradhan,Mark J. Henderson,Wei Zhu,Eunkeu Oh,Kimihiro Susumu,Mason A. Wolak,Khalida Shamim,Wenwei Huang,Xin Hu,Min Shen,Carleen Klumpp-Thomas,Zina Itkin,Paul Shinn,Juan Carlos de la Torre,Anton Simeonov,Sam Michael,Matthew D. Hall,Donald C. Lo,Wei Zheng +25 more
TL;DR: In this article, the authors evaluated six lysosomotropic compounds to identify an alternative Lysosome-based drug repurposing opportunity and found that six of these compounds blocked the cytopathic effect of SARS-CoV-2.
81
Discovery of a novel inhibitor of kinesin-like protein KIFC1
Wei Zhang,Ling Zhai,Yimin Wang,Rebecca J. Boohaker,Wenyan Lu,Vandana V. Gupta,Indira Padmalayam,Robert Bostwick,E. Lucile White,Larry J. Ross,Joseph A. Maddry,Subramaniam Ananthan,Corinne E. Augelli-Szafran,Mark J. Suto,Bo Xu,Rongbao Li,Yonghe Li +16 more
TL;DR: SR31527 prevented bipolar clustering of extra centrosomes in triple negative breast cancer (TNBC) cells and significantly reduced TNBC cell colony formation and viability, but was less toxic to normal fibroblasts.
Cellular HTS Assays for Pharmacological Characterization of NaV1.7 Modulators
Shephali Trivedi,Kim Dekermendjian,Ronald Julien,Jian Huang,Per-Eric Lund,Johannes J. Krupp,Robert Kronqvist,Olof Larsson,Robert Bostwick +8 more
TL;DR: This paper describes the first comparison between all the HTS assays available today to study voltage-gated NaVs, and the results suggest that the Li-AAS assay is more suited as a first HTS assay when starting an NaV drug discovery campaign.